Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Serratrice

Showing results (471-480 of 488) with videos related to

Pageof 49
Sort By:
Psychoneuroendocrinology|April 27, 2023
Acute TNFα levels predict cognitive impairment 6-9 months after COVID-19 infectionA Nuber-Champier, A Cionca, G Breville, et al.
Brain Communications|July 7, 2023
Markers of limbic system damage following SARS-CoV-2 infectionMarine Thomasson, Philippe Voruz, Alexandre Cionca, et al.
Human Brain Mapping|December 2, 2022
Brain functional connectivity alterations associated with neuropsychological performance 6-9 months following SARS-CoV-2 infectionPhilippe Voruz, Alexandre Cionca, Isabele Jacot de Alcântara, et al.
Orphanet Journal of Rare Diseases|October 28, 2025
French national diagnosis and care protocol (Protocole National De Diagnostic et de Soins; PNDS): Gaucher diseaseFabrice Camou, Christine Serratrice, Magali Pettazzoni, et al.
BMJ Open|November 29, 2024
Protocol for a multicentric, double-blind, randomised controlled trial of hyperbaric oxygen therapy (HBOT) versus sham for treating vaso-occlusive crisis (VOC) in sickle cell disease (SCD) in patients aged 8 years or older (HBOT-SCD study)Jerome Stirnemann, Jacques Serratrice, Tamara Mann, et al.
QJM : Monthly Journal of the Association of Physicians|March 22, 2013
Cryptococcosis in sarcoidosis: cryptOsarc, a comparative study of 18 casesC Bernard, D Maucort-Boulch, L Varron, et al.
Orphanet Journal of Rare Diseases|October 11, 2012
The French Gaucher's disease registry: clinical characteristics, complications and treatment of 562 patientsJérôme Stirnemann, Marie Vigan, Dalil Hamroun, et al.
Journal of Clinical Medicine|July 26, 2020
A Cross-Sectional Retrospective Study of Non-Splenectomized and Never-Treated Patients with Type 1 Gaucher DiseaseChristine Serratrice, Jérôme Stirnemann, Amina Berrahal, et al.
International Journal of Molecular Sciences|February 20, 2020
Immunoglobulin Abnormalities in Gaucher Disease: an Analysis of 278 Patients Included in the French Gaucher Disease RegistryYann Nguyen, Jérôme Stirnemann, Florent Lautredoux, et al.
Journal of Internal Medicine|February 28, 2026
Increased intervals in enzyme replacement therapy for stable type 1 Gaucher disease: A non-inferiority sequential trial emulationMaxime Beydon, Jérôme Stirnemann, Karima Yousfi, et al.
Pageof 49

Showing results (471-480 of 488) with videos related to

Sort By:
Pageof 49
Psychoneuroendocrinology|April 27, 2023
Acute TNFα levels predict cognitive impairment 6-9 months after COVID-19 infectionA Nuber-Champier, A Cionca, G Breville, et al.
Brain Communications|July 7, 2023
Markers of limbic system damage following SARS-CoV-2 infectionMarine Thomasson, Philippe Voruz, Alexandre Cionca, et al.
Human Brain Mapping|December 2, 2022
Brain functional connectivity alterations associated with neuropsychological performance 6-9 months following SARS-CoV-2 infectionPhilippe Voruz, Alexandre Cionca, Isabele Jacot de Alcântara, et al.
Orphanet Journal of Rare Diseases|October 28, 2025
French national diagnosis and care protocol (Protocole National De Diagnostic et de Soins; PNDS): Gaucher diseaseFabrice Camou, Christine Serratrice, Magali Pettazzoni, et al.
BMJ Open|November 29, 2024
Protocol for a multicentric, double-blind, randomised controlled trial of hyperbaric oxygen therapy (HBOT) versus sham for treating vaso-occlusive crisis (VOC) in sickle cell disease (SCD) in patients aged 8 years or older (HBOT-SCD study)Jerome Stirnemann, Jacques Serratrice, Tamara Mann, et al.
QJM : Monthly Journal of the Association of Physicians|March 22, 2013
Cryptococcosis in sarcoidosis: cryptOsarc, a comparative study of 18 casesC Bernard, D Maucort-Boulch, L Varron, et al.
Orphanet Journal of Rare Diseases|October 11, 2012
The French Gaucher's disease registry: clinical characteristics, complications and treatment of 562 patientsJérôme Stirnemann, Marie Vigan, Dalil Hamroun, et al.
Journal of Clinical Medicine|July 26, 2020
A Cross-Sectional Retrospective Study of Non-Splenectomized and Never-Treated Patients with Type 1 Gaucher DiseaseChristine Serratrice, Jérôme Stirnemann, Amina Berrahal, et al.
International Journal of Molecular Sciences|February 20, 2020
Immunoglobulin Abnormalities in Gaucher Disease: an Analysis of 278 Patients Included in the French Gaucher Disease RegistryYann Nguyen, Jérôme Stirnemann, Florent Lautredoux, et al.
Journal of Internal Medicine|February 28, 2026
Increased intervals in enzyme replacement therapy for stable type 1 Gaucher disease: A non-inferiority sequential trial emulationMaxime Beydon, Jérôme Stirnemann, Karima Yousfi, et al.
Pageof 49